Targeted interventions directed at reducing the levels of circulating succinate in a subject, and kits and method for determining effectiveness of said interventions

MÉS INFORMACIÓ

Dades d'interès

  • Technology Readiness Level

    TRL 4

  • Desired business relationship

    Looking for a partner interested in a license and/or a collaboration agreement to develop and exploit this asset.

  • Inventors

    Fernández-Veledo, Sonia; Serena Perelló, Carolina; Vendrell Ortega, Joan Josep; Ceperuelo Mallafré, Victòria; Calvo Manso, Enrique

  • Priority Date

    17.01.2018

  • International Application No.

    PCT/EP2019/051157

  • Publication number

    WO/2019/141780

  • Contact

    isabel.huber@iispv.cat

Targeted interventions directed at reducing the levels of circulating succinate in a subject, and kits and method for determining effectiveness of said interventions

Innovation & Description:

Succinate is a metabolite produced both by both human cells and gut microbiota that acts as a proinflammatory stimulus regulating local stress, tissue damage and immunologic danger. Circulating succinate is elevated in obese and diabetic 2 patients and is linked to a specific gut microbiota signature, thus constituting a new metabolic node in the control of obesity-related inflammation. We aim to develop a probiotic-based intervention to improve obesity-related disorders by diminishing circulating succinate levels. We will also develop a succinate-detection kit as a companion diagnostic that will support the correct selection of the patients and their follow-up.

  • Problem

    Obesity and type 2 diabetes are global challenges of epidemic proportions and need new multidimensional and personalized approaches

  • Problem to solve

    Obesity is a multifactorial disorder of epidemic proportions and its related co-morbidities call for a multidimensional and personalized treatment. Gut microbiota contributes to obesity, diabetes and related metabolic diseases. Indeed, gut dysbiosis is one of the major factors underlying the obesity-related inflammatory environment. However, probiotics are still not used within the common clinical practice. In a society where the demand for probiotics is sharply increasing, the science-driven identification and characterization of new probiotic strategies is needed to ensure their rational use and boost their implementation in the clinic.

  • Market and advantages of the technology

    The present invention comprises a kit to measure the ratio of succinate-producing bacteria to succinate-consuming bacteria, a diet intervention and a pharmacological or probiotic product directed at modifying the ratio of succinate-producing bacteria to succinate-consuming bacteria in order to improve metabolic profile of obese patients.

  • Stage of Development

    Obese and type 2 diabetic patients show elevated succinate levels and gut dysbiosis, which are major factors underlying obesity-related inflammation.

    A probiotic intervention to improve obesity-related disorders by diminishing circulating succinate levels and a companion diagnostics kit to select and follow up patients

  • Partners

    INSTITUT D’INVESTIGACIÓ SANITÀRIA PERE VIRGILI (IISPV)

    CONSORCIO CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED (CIBER)

    UNIVERSITAT ROVIRA I VIRGILI (URV)

    INSTITUT D’INVESTIGACIÓ BIOMÈDICA DE BELLVITGE (IDIBELL)

    FUNDACIÓ INSTITUT MAR D’INVESTIGACIONS BIOMÈDIQUES (IMIM)

Enllaços